Quick Answer
Vistagen Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $67.13 million for the year ending 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -43.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Vistagen Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
- XBRL data for this metric is available from 2010 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2010 to 2025), Vistagen Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 33,298.5%.
- Historical annual values: Fiscal year 2025: $67.13 million | Fiscal year 2024: $119.17 million | Fiscal year 2023: $16.64 million | Fiscal year 2022: $68.14 million | Fiscal year 2021: $103.11 million | Fiscal year 2020: $1.36 million | Fiscal year 2019: $13.10 million | Fiscal year 2018: $10.38 million | Fiscal year 2017: $2.92 million | Fiscal year 2016: $428.5 thousand | Fiscal year 2015: $70.0 thousand | Fiscal year 2013: $638.1 thousand | Fiscal year 2012: $81.0 thousand | Fiscal year 2011: $139.3 thousand | Fiscal year 2010: $201.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: